Next-Generation Thrombectomy

Focused on providing effective and easy-to-use clot removal to efficiently treat venous thromboembolisms


Venous Thromboembolism

Human Body

Deep Vein Thrombosis (DVT)

Blood clot in a deep vein, usually in the leg

Deep Vein Thrombosis
Pulmonary Embolism

Pulmonary Embolism (PE)

Blood clot travels from the leg to the lung, blocking flow

900K cases

in the U.S. each year1

100K deaths

in the U.S. each year1

3rd leading

cardiovascular cause of death behind heart attack and stroke2

Limitations with current treatments:


  • High Bleeding Risk
  • Requires ICU Monitoring
  • Lengthy treatment time before symptoms subside
  • Doesn’t address high-risk emergent situations

Mechanical Thrombectomy Devices

  • Inefficient
  • Procedurally Complex
  • Blood Loss
  • Difficulty reaching target
Three Icons

Our Solution

Simplifying Thrombectomy

Icon of Clot being broken up

Efficient Clot Removal

Catheter collects and breaks up large, mixed morphology clots

Icon of Catheter

Single-pass Procedure

Low-profile catheter navigates tortuous anatomy without crossing the clot

Icon of Person and Checkmark

Easy to Use

Simple setup with compact equipment


Akura Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

Murali Srivathsa

Murali Srivathsa

President & CEO

David Voris

David Voris

Chief Financial Officer

Aadel Al-Jadda

Aadel Al-Jadda

Co-Founder & VP of R&D

Joann Heberer

Joann Heberer

Senior Vice President

Praveen Dala

Praveen Dala

Vice President, Console

Amr Salaheih

Amr Salahieh

Co-Founder and Chairman

Mariam Maghribi

Mariam Maghribi

Chief Business Officer

Debbie White

Debbie White

SVP Human Resources

Robert Edesess

Robert Edesess

Vice President,
Intellectual Property

Interested in joining the team?

View open positions with Akura Medical and Shifamed’s other portfolio companies.

Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.


Akura Medical, a Shifamed Portfolio Company, Closes $35M in Series B Financing

Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing. The funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities.

read more

MedTech Strategist Article – Great Aspirations: New Mechanical Approaches to Treating Pulmonary Embolism

Just over a year ago, Murali Srivathsa joined Akura Medical as CEO, leaving his position as the head of global marketing for Abbott’s heart failure division. With 25 years of experience in commercial and marketing roles, including multiple exits in the cardiac space, Srivathsa believes that mechanical treatment of venous thromboembolism (VTE), which encompasses both PE and deep vein thrombosis (DVT), is on the cusp of strong growth. “There is a fair amount of competition here and a lot of new players trying to enter the market, which I feel is good because the market has low penetration and there are many patients that need this technology,” he says.

read more

Akura Medical Announces Successful First-in-Human Use of its High Performance Mechanical Thrombectomy Platform

Los Gatos, Calif., May 10, 2023 – Akura Medical, a Shifamed portfolio company focused on a differentiated approach delivering an effective solution to address the major challenges of venous thromboembolism (VTE), announced today it has initiated its first-in-human clinical study of the Akura Mechanical Thrombectomy Platform. The Akura platform is a low-profile solution designed to easily access and efficiently remove large volume, mixed morphology clots, and eliminate the guesswork around the procedure. The initial 5 cases were performed in the Republic of Georgia and marked the first use of mechanical thrombectomy for pulmonary embolism (PE) in the country.

read more